Michelle Nagtegaal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michelle Nagtegaal has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Rick Robert van Rijn
Amsterdam University Medical Centers, Amsterdam, Netherlands
3 shared publications - Simon G. F. Robben
Maastricht University Medical Center
2 shared publications A.H. Teeuw
1 shared publication- Annebeth Meij-De Vries
Alliance of Dutch Burn Care, Burn Center Beverwijk, Red Cross Hospital, Vondellaan 13, 1942 LE Beverwijk, The Netherlands
1 shared publication - Bart de Keizer
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
1 shared publication - Charles E. H. Berger
Netherlands Forensic Institute, The Hague, the Netherlands; Leiden University, Leiden, the Netherlands
1 shared publication
Latest Publications
- 17 September 2026
- Published by Springer Nature
- p. 1-23
Abusive Head Trauma
- 29 April 2025
- Published by Springer Nature
- p. 277-297
Post Mortem Imaging in Suspected Physical Abuse
- Open Access
Comment on van Gemert et al. Child Abuse, Misdiagnosed by an Expertise Center—Part II—Misuse of Bayes’ Theorem. Children 2023, 10, 843
Recently, part I and part II of a series of three papers were published, namely the papers by Vlaming et al
Open AccessComment on van Gemert et al. Child Abuse, Misdiagnosed by an Expertise Center—Part II—Misuse of Bayes’ Theorem. Children 2023, 10, 843
Recently, part I and part II of a series of three papers were published, namely the papers by Vlaming et al
- 11 June 2023
- Published by Springer Nature
- p. 203-232
Spine
- Open Access
- 17 November 2019
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (4) , e28061
Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease
Background: The clinical course of neuroblastoma stage 4S or MS is characterized by a high rate of spontaneous tumor regression and favorable outcome. However, the clinical course and rate of the regression are poorly understood.Methods: A retrospective cohort study was performed, including all patients with stage 4S neuroblastoma without MYCN amplification, from two Dutch centers between 1972 and 2012. We investigated the clinical characteristics, the biochemical activity reflected in urinary catecholamine excretion, and radiological imaging to describe the kinetics of tumor regression, therapy response and outcome.Results: The cohort of 31 patients reached a 10‐year overall survival of 84% ± 7% (median follow‐up 16 years; range, 3.3‐39). During the regressive phase, liver size normalized in 91% of the patients and catecholamine excretion in 83%, both after a median of two months (liver size: range, 0‐131; catecholamines: range, 0‐158). The primary tumors completely regressed in 69% after 13 months (range, 6‐73), and the liver architecture normalized in 52% after 15 months (range, 5‐131). Antitumor treatment was given in 52% of the patients. Interestingly, regression rates were similar for treated and untreated patients. Four of seven patients < 4 weeks old died of rapid liver expansion and organ compression. Three patients progressed to stage 4, 3 to 13 months after diagnosis; all had persistently elevated catecholamines.Conclusion: Patients < 4 weeks old with neuroblastoma stage 4S are at risk of fatal outcome caused by progression of liver metastases. In other patients, tumor regression is characterized by a rapid biochemical normalization that precedes radiological regression.
- 17 November 2019
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (4) , e28061
Open AccessNeuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease
Background: The clinical course of neuroblastoma stage 4S or MS is characterized by a high rate of spontaneous tumor regression and favorable outcome. However, the clinical course and rate of the regression are poorly understood.Methods: A retrospective cohort study was performed, including all patients with stage 4S neuroblastoma without MYCN amplification, from two Dutch centers between 1972 and 2012. We investigated the clinical characteristics, the biochemical activity reflected in urinary catecholamine excretion, and radiological imaging to describe the kinetics of tumor regression, therapy response and outcome.Results: The cohort of 31 patients reached a 10‐year overall survival of 84% ± 7% (median follow‐up 16 years; range, 3.3‐39). During the regressive phase, liver size normalized in 91% of the patients and catecholamine excretion in 83%, both after a median of two months (liver size: range, 0‐131; catecholamines: range, 0‐158). The primary tumors completely regressed in 69% after 13 months (range, 6‐73), and the liver architecture normalized in 52% after 15 months (range, 5‐131). Antitumor treatment was given in 52% of the patients. Interestingly, regression rates were similar for treated and untreated patients. Four of seven patients < 4 weeks old died of rapid liver expansion and organ compression. Three patients progressed to stage 4, 3 to 13 months after diagnosis; all had persistently elevated catecholamines.Conclusion: Patients < 4 weeks old with neuroblastoma stage 4S are at risk of fatal outcome caused by progression of liver metastases. In other patients, tumor regression is characterized by a rapid biochemical normalization that precedes radiological regression.